American multinational pharma leader behind GLP-1 drugs and blockbuster therapies
On April 2, 2026, President Trump signed executive orders imposing up to 100% tariffs on foreign-made patented pharmaceuticals that do not meet pricing or US manufacturing conditions. Companies with pricing deals and US production face zero tariffs; others face escalating tariffs over four years. The orders also revise tariffs on steel, aluminum, and copper products to be based on full US market value.
Recent studies have shown significant advances in gene therapy for hearing loss and eye conditions, as well as promising research on reversing brain inflammation linked to aging. Meanwhile, new evidence questions the effectiveness of Alzheimer’s drugs, highlighting ongoing challenges in neurodegenerative treatments. Today's date is Mon, 27 Apr 2026 11:37:39 +0100.
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
A wave of AI-related IPOs from SpaceX, Anthropic and OpenAI is unfolding, with markets facing a flood of new stock. Retail demand remains strong for SpaceX, but analysts warn supply could overwhelm demand, pressuring prices and testing market resilience.
GSK has struck a multi-billion deal to acquire Nuvalent, adding three late-stage cancer drugs to its portfolio, including two lung-cancer therapies under FDA review. The acquisition aims to boost sales growth, expand the lung-cancer platform, and position GSK for a potential rise in annual revenue by 2031.
Three articles report on cutting-edge biotech and AI-driven medicine: base editing in embryos stirs debate over cures and designer babies; Google-backed AI seeks clinical trust; Life Biosciences tests cellular reprogramming in humans to combat aging and glaucoma.
A wave of weight-loss drugs is reshaping employer coverage, consumer use, and government pricing. Oral GLP-1 pills have launched in the US and UK, intensifying cost pressures for employers and payers while private uptake grows. Regulators and insurers are debating coverage, while manufacturers are cutting prices and expanding access.
Global markets drift as AI-linked tech rotates out of leadership roles while oil prices oscillate on Iran talks. The S&P 500 has been fluctuating, tech giants weigh on indices, and energy names are moving with crude. Investors monitor inflation signals as Fed policy looms.
Pennsylvania has rolled out stricter guardrails for data center projects, including energy cost commitments, community engagement, and environmental protections. The move aims to accelerate development while addressing local concerns. Projects like Boson and The Highland are cited as tests of the new framework amid bipartisan push for faster permitting.
POLITICO, Independent, Business Insider UK and others report on RAISE US, a bipartisan nonprofit led by Gina Raimondo and Eric Holcomb. The group mobilizes $500m+ from tech firms to fund workforce programs, pilots in Arkansas, Maryland, Utah and Connecticut, and policy work to shield workers from AI disruption.